By Kuldip K. Ambastha
The stock of Regeneron Pharmaceuticals, Inc. (REGN), a biotechnology company with a portfolio of medicines for individuals with serious diseases, increased in price by +18.8% per share on the trading day of Thursday, September 8, 2022. Eylea (aka: aflibercept), an anti-blindness eye medication, was the cause of this price run-up, because of positive results seen in two late-stage trials. The latest data from the trials supports the safe use of Eylea in potentially higher dosages (such as 8 mg) with longer dosing intervals (such as 16 weeks). Various Wall Street equity research analysts have upgraded the stock and / or raised the price target on the stock due to the strongly positive observed data. Eylea has been a strong revenue generator for Regeneron thus far and likely may continue to be a strong revenue generator in the future.
Keywords – Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Regeneron, biotechnology, biotech, medicine, medication, Eylea, aflibercept, late-stage, trial, anti-blindness, eye, Wall Street, equity research, upgrade, price, revenue.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in REGN.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.